AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20865580 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 50
Study 20865580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received standard anesthetic protocol and IV morphine via PCA
Number of subjects: 50
Study 18927140 — intervention group
Group type: EXPERIMENTAL
Intervention: Family CBT
Number of subjects: 0
Study 18927140 — intervention group
Group type: COMPARATOR
Intervention: Individual CBT
Number of subjects: 0
Study 16642606 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 'Kaiyin point No. 1', once daily for 7 days.
Number of subjects: 160
Study 16642606 — intervention group
Group type: COMPARATOR
Intervention: Spray inhalation of western medicine, once daily for 7 days.
Number of subjects: 160
Study 14657775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 12
Study 14657775 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 12
Study 11108404 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (three-day workshop with lectures, videos, role-plays, interviews, demonstrations)
Number of subjects: 149
Study 11108404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149
Study 8977750 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) followed 120 minutes later by hexarelin (1 microgram/kg i.v.)
Number of subjects: 18
Study 8977750 — intervention group
Group type: COMPARATOR
Intervention: Hexarelin (1 microgram/kg i.v.) followed 120 minutes later by GHRH (1 microgram/kg i.v.)
Number of subjects: 18
Study 8977750 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) followed 120 minutes later by GHRH (1 microgram/kg i.v.)
Number of subjects: 18
Study 8977750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (1 microgram/kg i.v.) followed 120 minutes later by hexarelin (1 microgram/kg i.v.)
Number of subjects: 18
Study 8977750 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.5 IU i.v.) followed 120 minutes later by GHRH (1 microgram/kg i.v.)
Number of subjects: 18
Study 8977750 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.5 IU i.v.) followed 120 minutes later by hexarelin (1 microgram/kg i.v.)
Number of subjects: 18
Study 1623513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg)
Number of subjects: 25
Study 1623513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6482920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin alone
Number of subjects: 145
Study 6482920 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and gentamicin together
Number of subjects: 145
Study 6482920 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative sepsis
Number of subjects: 145
Study 6482920 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for infection
Number of subjects: 145
Study 31775418 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA) with 0.25% lidocaine and 1.33% lidocaine
Number of subjects: 120
Study 31775418 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) with propofol, sufentanil, and cisatracurium
Number of subjects: 120
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in Neck Disability Index (NDI) score at 24 months
Number of subjects: 512
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute NDI score at 24 months
Number of subjects: 512
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute VAS neck pain score at 24 months
Number of subjects: 512
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in NDI score at 60 months
Number of subjects: 512
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute NDI score at 60 months
Number of subjects: 512
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in VAS neck pain score at 60 months
Number of subjects: 512
Study 28254671 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute VAS neck pain score at 60 months
Number of subjects: 512
Study 25179578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 25179578 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 0
Study 23829039 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable interface
Number of subjects: 8
Study 23829039 — intervention group
Group type: COMPARATOR
Intervention: Desktop simulator
Number of subjects: 8
Study 23829039 — intervention group
Group type: COMPARATOR
Intervention: Interactive training video
Number of subjects: 8
Study 23829039 — intervention group
Group type: EXPERIMENTAL
Intervention: Live training environment
Number of subjects: 8
Study 23055414 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg) with mirtazapine
Number of subjects: 43
Study 23055414 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg) with placebo
Number of subjects: 43
Study 18793768 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser zona thinning
Number of subjects: 84
Study 16935794 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Vitreoscilla filiformis (V.f.) extract-containing ointment
Number of subjects: 13
Study 16935794 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 13
Study 15347562 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB (apnea-hypopnea index > or = 5) in men
Number of subjects: 457
Study 15347562 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB (apnea-hypopnea index > or = 5) in women
Number of subjects: 457
Study 15347562 — intervention group
Group type: EXPERIMENTAL
Intervention: OSAS (apnea-hypopnea index > or = 5 plus excessive daytime sleepiness) in men
Number of subjects: 457
Study 15347562 — intervention group
Group type: EXPERIMENTAL
Intervention: OSAS (apnea-hypopnea index > or = 5 plus excessive daytime sleepiness) in women
Number of subjects: 457
Study 11502788 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (Premarin, 0.625 mg/d)
Number of subjects: 26
Study 11502788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9009974 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNW plan (prepackaged meals)
Number of subjects: 560
Study 9009974 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet (AHA Step I and II)
Number of subjects: 560
Study 8518245 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally applied oestradiol (50 micrograms/24 h)
Number of subjects: 52
Study 8518245 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally applied oestradiol (100 micrograms/24 h)
Number of subjects: 52
Study 8518245 — intervention group
Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (5 mg daily)
Number of subjects: 52
Study 3450443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 20
Study 3450443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30259145 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL injury prevention program (ACL‐IPP) for 6 weeks
Number of subjects: 43
Study 30259145 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to ACL injury prevention program (ACL‐IPP)
Number of subjects: 43
Study 31026242 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐ON CXL (iontophoretic transepithelial collagen cross-linking)
Number of subjects: 28
Study 31026242 — intervention group
Group type: COMPARATOR
Intervention: Epi‐off CXL (epithelium-off collagen cross-linking)
Number of subjects: 28
Study 29234748 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐incorporated titanium implants (Xpeed)
Number of subjects: 60
Study 29234748 — intervention group
Group type: COMPARATOR
Intervention: Control resorbable blasted media (RBM) implants
Number of subjects: 60
Study 25277347 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-Lymphocyte Ratio (NLR)
Number of subjects: 3262
Study 25277347 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 3262
Study 23537965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy specialist-, telephone-administered intervention
Number of subjects: 0
Study 23537965 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg on alternate days
Number of subjects: 27939
Study 22090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction-based treatment using the newly developed model
Number of subjects: 27939
Study 22090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective treatment of women >65 years of age
Number of subjects: 27939
Study 22090661 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 27939
Study 22090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 27939
Study 22090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking and baseline risk for cardiovascular events
Number of subjects: 27939
Study 22090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment strategy
Number of subjects: 27939
Study 19673814 — intervention group
Group type: EXPERIMENTAL
Intervention: music-supported therapy
Number of subjects: 32
Study 19673814 — intervention group
Group type: COMPARATOR
Intervention: standard rehabilitation procedures
Number of subjects: 32
Study 16465651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy (oral tetracycline 250 mg twice daily, 3 times per week, and intravenous clindamycin infused on 5 consecutive days with varying dosages followed by weekly and fortnightly infusions for 12 months)
Number of subjects: 21
Study 16465651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy
Number of subjects: 21
Study 16465651 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (control group)
Number of subjects: 21
Study 15057737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 56 days
Number of subjects: 32
Study 15057737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 56 days with eradication of H. pylori during the last week of treatment
Number of subjects: 32
Study 11902249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisofylline (3 mg/kg, max 300 mg IV every 6 hrs for 20 days or until 48 hrs of unassisted breathing)
Number of subjects: 235
Study 11902249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 11902249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisofylline
Number of subjects: 235
Study 9673781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BDP (0.2, 0.5, 1, 2 or 5 mg)
Number of subjects: 40
Study 9673781 — intervention group
Group type: COMPARATOR
Intervention: Inhaled HFA BDP (0.2 or 0.8 mg)
Number of subjects: 40
Study 7643880 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 1934
Study 7643880 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1934
Study 2502168 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg kg‐1
Number of subjects: 50
Study 2502168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg kg‐1
Number of subjects: 50
Study 953956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl-CCNU and vincristine
Number of subjects: 92
Study 953956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl-CCNU, vincristine, and methotrexate
Number of subjects: 92
Study 953956 — intervention group
Group type: COMPARATOR
Intervention: Methyl-CCNU alone
Number of subjects: 92
Study 29687232 — intervention group
Group type: EXPERIMENTAL
Intervention: English double-embedded sentences without middle verb phrase
Number of subjects: 0
Study 29687232 — intervention group
Group type: COMPARATOR
Intervention: Dutch double-embedded sentences without middle verb phrase
Number of subjects: 0
Study 28709470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training with oxytocin administration
Number of subjects: 100
Study 28709470 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Bias Modification (CBM) training with placebo
Number of subjects: 100
Study 28709470 — intervention group
Group type: COMPARATOR
Intervention: Placebo training with oxytocin administration
Number of subjects: 100
Study 28709470 — intervention group
Group type: COMPARATOR
Intervention: Placebo training with placebo
Number of subjects: 100
Study 24931003 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca (3.3 g/day for 6 weeks)
Number of subjects: 29
Study 24931003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 weeks)
Number of subjects: 29
Study 23814237 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM
Number of subjects: 397
Study 23814237 — intervention group
Group type: COMPARATOR
Intervention: MoP
Number of subjects: 397
Study 23814237 — intervention group
Group type: COMPARATOR
Intervention: CoP
Number of subjects: 397
Study 22196062 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sevoflurane with 4 L/min O₂ for 3 minutes
Number of subjects: 30
Study 22196062 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-sevoflurane) with 4 L/min O₂ alone
Number of subjects: 30
Study 22196062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (sevoflurane and non-sevoflurane)
Number of subjects: 30
Study 18676056 — intervention group
Group type: EXPERIMENTAL
Intervention: 20Gy of radiation in 2 weeks followed by two courses of chemotherapy (paclitaxel 180mg/m², cisplatin 45mg/m², ifosfamide 1000mg/m²)
Number of subjects: 35
Study 18676056 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion radiotherapy of additional 45Gy
Number of subjects: 35
Study 18676056 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for patients with stages IB, IIA, and IIB
Number of subjects: 35
Study 18676056 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for patients with stages IIIA and IIIB
Number of subjects: 35
Study 18676056 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment related morbidity
Number of subjects: 35
Study 17519056 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 38
Study 17519056 — intervention group
Group type: COMPARATOR
Intervention: Same-room treatment
Number of subjects: 38
Study 15189943 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) 24 micro g/kg/h, continuous IV infusion for 96 ± 1 h
Number of subjects: 273
Study 15189943 — intervention group
Group type: COMPARATOR
Intervention: Drotrecogin alfa (activated)
Number of subjects: 273
Study 15189943 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups from PROWESS US trial
Number of subjects: 273
Study 15189943 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups from sPLA2I trial
Number of subjects: 273
Study 15189943 — intervention group
Group type: COMPARATOR
Intervention: Drotrecogin alfa (activated) in PROWESS US trial
Number of subjects: 273
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (1.5 g/kg/day) with [(15)N]alanine
Number of subjects: 12
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake (0.3 g/kg/day) with [(15)N]alanine
Number of subjects: 12
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (1.5 g/kg/day) with [(15)N]Spirulina platensis
Number of subjects: 12
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake (0.3 g/kg/day) with [(15)N]Spirulina platensis
Number of subjects: 12
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with [(15)N]alanine
Number of subjects: 12
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with [(15)N]Spirulina platensis
Number of subjects: 12
Study 11440912 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with IDDM consuming test meal with [(15)N]alanine
Number of subjects: 12
Study 10051934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 100
Study 10051934 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 100
Study 7973475 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 7.5 mg/week and CHLO 250 mg/day
Number of subjects: 82
Study 7973475 — intervention group
Group type: COMPARATOR
Intervention: MTX 7.5 mg/week and PLA 1 tablet/day
Number of subjects: 82
Study 30342256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (depression prevention program)
Number of subjects: 150
Study 30342256 — intervention group
Group type: COMPARATOR
Intervention: Health education group (didactic control)
Number of subjects: 150
Study 30342256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 150
Study 30342256 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 150
Study 27753600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3199
Study 27753600 — intervention group
Group type: COMPARATOR
Intervention: UFH plus GPI
Number of subjects: 3199
Study 25440560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya and related practices (SK&P) for six weeks
Number of subjects: 230
Study 25440560 — intervention group
Group type: COMPARATOR
Intervention: Control group (sitting in an armchair with eyes closed and gentle attention to breath for six weeks)
Number of subjects: 230
Study 22524487 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 100
Study 22524487 — intervention group
Group type: COMPARATOR
Intervention: Fastrach (FT)
Number of subjects: 100
Study 20687940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 60 min specific strength training with training supervision
Number of subjects: 2000
Study 20687940 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 20 min specific strength training with training supervision
Number of subjects: 2000
Study 20687940 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 x 7 min specific strength training with training supervision
Number of subjects: 2000
Study 20687940 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 20 min specific strength training with minimal supervision
Number of subjects: 2000
Study 20687940 — intervention group
Group type: COMPARATOR
Intervention: Reference group without training
Number of subjects: 2000
Study 18716531 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with xylocaine
Number of subjects: 115
Study 18716531 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular oral analgesics
Number of subjects: 115
Study 18716531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 18716531 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 115
Study 18716531 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine oral analgesics
Number of subjects: 115
Study 16643392 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal pacing
Number of subjects: 28
Study 16643392 — intervention group
Group type: COMPARATOR
Intervention: Apical pacing
Number of subjects: 28
Study 12855302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride frequency (F) at 1 Hz
Number of subjects: 8
Study 12855302 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller stride length (L)
Number of subjects: 8
Study 12855302 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely chosen walking speeds
Number of subjects: 8
Study 10985269 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal process analysis and implementation of new practice guidelines
Number of subjects: 37
Study 10985269 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal process analysis phase
Number of subjects: 37
Study 10985269 — intervention group
Group type: COMPARATOR
Intervention: Before implementation
Number of subjects: 37
Study 10985269 — intervention group
Group type: EXPERIMENTAL
Intervention: After implementation
Number of subjects: 37
Study 10985269 — intervention group
Group type: EXPERIMENTAL
Intervention: During formal process analysis
Number of subjects: 37
Study 8799540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 86
Study 8799540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 1735859 — intervention group
Group type: EXPERIMENTAL
Intervention: Three radial incisions at 12, 4 and 8 o'clock
Number of subjects: 16
Study 1735859 — intervention group
Group type: COMPARATOR
Intervention: Four radial incisions at 12, 3, 6, and 9 o'clock
Number of subjects: 16
Study 1735859 — intervention group
Group type: EXPERIMENTAL
Intervention: Three radial incisions
Number of subjects: 16
Study 1735859 — intervention group
Group type: COMPARATOR
Intervention: Four radial incisions
Number of subjects: 16
Study 6385206 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol (1500 mg X 2)
Number of subjects: 36
Study 6385206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29676980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HP gel (low viscosity)
Number of subjects: 120
Study 29676980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HP gel (medium viscosity)
Number of subjects: 120
Study 29676980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HP gel (high viscosity)
Number of subjects: 120
Study 29676980 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest 3D Whitestrips 1‐Hour Express
Number of subjects: 120
Study 29676980 — intervention group
Group type: COMPARATOR
Intervention: medium viscosity gel without HP (negative control)
Number of subjects: 120
Study 27479460 — intervention group
Group type: EXPERIMENTAL
Intervention: INCShort (n=12)
Number of subjects: 24
Study 27479460 — intervention group
Group type: COMPARATOR
Intervention: INCLong (n=12)
Number of subjects: 24
Study 25304787 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery
Number of subjects: 60
Study 25304787 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 60
Study 21840136 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate 5% mouthwash
Number of subjects: 36
Study 21840136 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 36
Study 20542081 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful action preparation
Number of subjects: 0